AA
ARQT icon

ALPS Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

ALPS Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,244
Closed -$443K – 1000
2023
Q1 		$443K Sell
40,244
-1,099
-3% -$15.9K ﹤0.01% 601
2022
Q4 		$612K Buy
41,343
+8,530
+26% +$149K 0.01% 555
2022
Q3 		$627K Buy
32,813
+2,314
+8% +$52.4K 0.01% 555
2022
Q2 		$650K Sell
30,499
-21,284
-41% -$437K 0.01% 539
2022
Q1 		$997K Sell
51,783
-6,420
-11% -$109K 0.01% 314
2021
Q4 		$1.21M Sell
58,203
-3,375
-5% -$67.2K 0.01% 337
2021
Q3 		$1.47M Sell
61,578
-4,546
-7% -$104K 0.01% 350
2021
Q2 		$1.8M Sell
66,124
-24,490
-27% -$690K 0.02% 339
2021
Q1 		$2.62M Buy
90,614
+21,589
+31% +$674K 0.03% 234
2020
Q4 		$1.94M Buy
69,025
+20,331
+42% +$498K 0.02% 288
2020
Q3 		$1.43M Sell
48,694
-3,359
-6% -$89.7K 0.02% 284
2020
Q2 		$1.57M Buy
+52,053
New +$1.5M 0.02% 260

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ALPS Advisors's ARQT Position: Q2 2023 in Review

ALPS Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 40,244 shares — an estimated $443K sold.

ALPS Advisors first reported a position in ARQT in Q2 2020 and held it in 12 quarters. The position peaked at $2.62M in Q1 2021. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • ALPS Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 40,244 Arcutis Biotherapeutics shares in Q2 2023, an estimated $443K.
  • ALPS Advisors first reported a position in Arcutis Biotherapeutics in Q2 2020 and held it in 12 quarters.
  • ALPS Advisors's Arcutis Biotherapeutics position peaked at $2.62M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.